{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-001828","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2022-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.407528+00:00","generated_at":"2026-06-27T06:28:50.813002+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO","bullets":["Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.","Annual base salary of $325,000; target bonus up to 40% of base salary.","Stock award of 25,000 shares and option to purchase 175,000 shares vesting over 3 years.","Options fully accelerate upon a change of control; employment agreement to be signed.","Ohri is a CPA with prior CFO experience at ToughBuilt Industries and Big 4 background."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-001828","json":"https://secwatch.observer/filing/0001654954-22-001828.json","markdown":"https://secwatch.observer/filing/0001654954-22-001828.md","text":"https://secwatch.observer/filing/0001654954-22-001828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/gtbp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:28:50.813002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38d49e3a57","claim":"Manu Ohri was appointed as Chief Financial Officer at GT Biopharma, Inc..","evidence_excerpt":"Effective February 14, 2022, the Registrant appointed Manu Ohri as the Registrant’s Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b7c8705ed8","claim":"Gavin Choy departed as Acting Chief Financial Officer at GT Biopharma, Inc..","evidence_excerpt":"Gavin Choy ceased serving as the Registrant’s Acting Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Acting Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}